CTI BioPharma Cash Flow Statement

Financials in millions EUR. Fiscal year is October - September.

Millions EUR. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2020
Period Ending	Mar '25 Mar 31, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	Sep '20 Sep 30, 2020	2016 - 2020
Net Income	8.18	8.32	10.64	8.38	7.34	6.5	Upgrade
Asset Writedown & Restructuring Costs	-	-	-2.64	-	-	-	Upgrade
Loss (Gain) From Sale of Investments	-	-	-	-	-	1	Upgrade
Other Operating Activities	-9.24	-9.33	-8.74	-8.33	-8.37	-8.19	Upgrade
Change in Accounts Receivable	-0	0.01	-	-	-	0.02	Upgrade
Change in Other Net Operating Assets	-0.04	-0.42	0.24	-0.85	-0.04	0.34	Upgrade
Operating Cash Flow	-1.1	-1.41	-0.5	-0.8	-1.07	-0.34	Upgrade
Investment in Securities	0.35	2.35	-0.53	-0.58	3.26	-1.05	Upgrade
Other Investing Activities	9.55	9.62	8.95	8.42	8.37	8.43	Upgrade
Investing Cash Flow	9.9	11.97	8.42	7.84	11.63	7.38	Upgrade
Common Dividends Paid	-7.74	-9.29	-6.97	-6.19	-9.29	-6.19	Upgrade
Other Financing Activities	-1.06	-1.27	-0.95	-0.85	-1.27	-0.85	Upgrade
Financing Cash Flow	-8.8	-10.56	-7.92	-7.04	-10.56	-7.04	Upgrade
Net Cash Flow	-	-	-0	-	-	-	Upgrade
Cash Interest Paid	-	-	-	0	-	-	Upgrade
Cash Income Tax Paid	-	-	-	-	-0	-0.27	Upgrade
Levered Free Cash Flow	0.18	-8.47	-10.61	-1.02	12.59	-1.18	Upgrade
Unlevered Free Cash Flow	0.19	-8.45	-10.59	-0.99	12.63	-1.14	Upgrade
Change in Net Working Capital	-0.91	7.81	10.1	0.58	-13.24	0.58	Upgrade

Updated Feb 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.